Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)

The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis. This drug was administered to 2 pediatric patients with purulent meningitis at the dose to 50 mg/kg, by intravenous drip infusion over 30 minutes and one shot intravenous injection respectively. When spinal fluid levels were determined, about 15 approximately 30% of the drug concentration in blood was found to transfer to spinal fluid at acute stage. Spinal fluid levels were about 4 approximately 7 micrograms/ml. When 4 pediatric patients with purulent meningitis were treated with the drug, the good results were obtained in all of them. The dose given was 200 approximately 300 mg/kg/day and the dosing duration was 14 approximately 22 days. No adverse reaction was noted, nor abnormal laboratory test values were noted.